ATRC - AtriCure, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.19
+0.02 (+0.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close27.17
Open27.42
Bid0.00 x 1300
Ask35.74 x 800
Day's Range27.02 - 27.43
52 Week Range26.11 - 36.49
Volume153,400
Avg. Volume197,778
Market Cap1.074B
Beta (3Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.56
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.50
Trade prices are not sourced from all markets
  • The Funded: 6 Bay Area companies raise $274M at midweek
    American City Business Journals

    The Funded: 6 Bay Area companies raise $274M at midweek

    Six Bay Area companies disclosed at midweek that that they raised $274 million in funding and a Redwood City medical device startup was acquired for as much as $300 million. Here are the details on those stories and more.

  • Business Wire

    AtriCure Completes Acquisition of SentreHEART

    AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions.

  • AtriCure could pay up to $300M to acquire California firm
    American City Business Journals

    AtriCure could pay up to $300M to acquire California firm

    AtriCure Inc. disclosed today that the Mason-based medical device maker could pay up to $300 million to acquire a California firm that also makes devices to treat heart ailments.

  • Business Wire

    AtriCure Enters Into Definitive Agreement to Acquire SentreHEART

    AtriCure, Inc. (ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has entered into a definitive agreement to acquire SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage management solutions. Under the terms of the agreement to acquire SentreHEART, the transaction consideration consists of an upfront payment of approximately $40 million in cash and AtriCure common stock, plus additional contingent consideration based on the achievement of certain clinical and reimbursement milestones over the next several years, all of which are value-creating events. Of the contingent consideration, $140 million is based on milestones related to the aMAZE™ IDE clinical trial, including PMA approval, and $120 million is based on a milestone related to reimbursement for the therapy involving SentreHEART devices.

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRC earnings conference call or presentation 30-Jul-19 8:30pm GMT

    Q2 2019 AtriCure Inc Earnings Call

  • AtriCure Inc (ATRC) Q2 2019 Earnings Call Transcript
    Motley Fool

    AtriCure Inc (ATRC) Q2 2019 Earnings Call Transcript

    ATRC earnings call for the period ending June 30, 2019.

  • AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

    AtriCure (ATRC) delivered earnings and revenue surprises of 5.56% and 2.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    AtriCure Reports Second Quarter 2019 Financial Results

    MASON, Ohio-- -- Worldwide revenue of $58.9 million – an increase of 13.7% year over year U.S. revenue of $47.2 million – an increase of 15.5% year over year International revenue of $11.7 million – an increase of 7.0% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced second quarter 2019 financial results. ...

  • ACCESSWIRE

    AtriCure, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July, 30 2019 / AtriCure, Inc. (NASDAQ: ATRC ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July, 30 2019 at 4:30:00 PM Eastern ...

  • AtriCure (NASDAQ:ATRC) May Be Weighed Down By Its Debt
    Simply Wall St.

    AtriCure (NASDAQ:ATRC) May Be Weighed Down By Its Debt

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know

    AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    AtriCure to Participate at the Canaccord Genuity 39th Annual Growth Conference

    AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that the company will be participating in the upcoming Canaccord Genuity 39th Annual Growth Conference in Boston.

  • GuruFocus.com

    Atricure Inc (ATRC) President, CEO, & Director Michael H Carrel Sold $800,000 of Shares

    President, CEO, & Director of Atricure Inc (ATRC) Michael H Carrel (insider trades) sold 25,000 shares of ATRC on 07/10/2019 at an average price of $32 a share. Continue reading...

  • Business Wire

    AtriCure to Announce Second Quarter 2019 Financial Results

    AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it will release its second quarter 2019 financial results on Tuesday, July 30, 2019.

  • Dayton's largest public company executive compensations
    American City Business Journals

    Dayton's largest public company executive compensations

    June's final Dayton Business Journal list took a look at the region's public company executive compensations. Of the 24 executives on our list, 66 percent received at least $1 million in total compensation in 2018.

  • Hedge Funds Have Never Been This Bullish On AtriCure Inc. (ATRC)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On AtriCure Inc. (ATRC)

    At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]

  • Is AtriCure, Inc. (NASDAQ:ATRC) Worth US$29.31 Based On Its Intrinsic Value?
    Simply Wall St.

    Is AtriCure, Inc. (NASDAQ:ATRC) Worth US$29.31 Based On Its Intrinsic Value?

    How far off is AtriCure, Inc. (NASDAQ:ATRC) from its intrinsic value? Using the most recent financial data, we'll take...

  • CNBC

    These stocks have 'underappreciated' stories, Wall Street analysts say

    Analysts named Corning, Target, Costco, AtriCure, and Coupa Software as having "underappreciated" stock stories. "Increased control over product supply is an underappreciated part of the Costco investment story," Baird analyst Peter Benedict said.

  • Hedge Funds Have Never Been More Bullish On AtriCure Inc. (ATRC)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On AtriCure Inc. (ATRC)

    The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRC earnings conference call or presentation 25-Apr-19 8:30pm GMT

    Q1 2019 AtriCure Inc Earnings Call

  • AtriCure Inc (ATRC) Q1 2019 Earnings Call Transcript
    Motley Fool

    AtriCure Inc (ATRC) Q1 2019 Earnings Call Transcript

    ATRC earnings call for the period ending March 31, 2019.

  • Associated Press

    AtriCure: 1Q Earnings Snapshot

    The Mason, Ohio-based company said it had a loss of 15 cents per share. Losses, adjusted for non-recurring gains, came to 20 cents per share. The results beat Wall Street expectations. The average estimate ...

  • Business Wire

    AtriCure Reports First Quarter 2019 Financial Results

    MASON, Ohio-- -- Worldwide revenue of $54.0 million – an increase of 14.8% year over year U.S. revenue of $43.0 million – an increase of 11.9% year over year International revenue of $11.0 million – an increase of 28.1% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced first quarter 2019 financial results. ...

  • Business Wire

    AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart

    AtriCure, Inc. (ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial (NCT02393885). Following approval by the FDA to restart the trial and enroll an additional 40 subjects, which was granted in December 2018, the first patient was treated by a team led by Professor Mark La Meir and Professor Carlo de Asmundis at Universitair Ziekenhuis Brussels, Belgium. The DEEP trial is a prospective, multicenter, single arm, investigational device exempt (IDE) study to evaluate the safety and efficacy of the DEEP procedure in treating persistent and long-standing persistent atrial fibrillation.